Literature DB >> 7826494

Prevalence of depression in Alzheimer's disease and validity of Research Diagnostic Criteria.

S Vida1, P Des Rosiers, L Carrier, S Gauthier.   

Abstract

This study was undertaken to estimate the point-prevalence of Research Diagnostic Criteria (RDC) depressive syndromes in Alzheimer's disease (AD) and to evaluate the validity of existing and potential alternative diagnostic criteria for major depression in the presence of probable AD. Twenty-six subjects with probable AD of mild to moderate severity and their caregivers were interviewed to estimate the prevalence of RDC depressive syndromes. For the evaluation of the validity of RDC for major depression, an additional 8 probable-AD subjects with suspected depression were added to the sample. Sensitivity, specificity, and correlation with diagnosis of RDC major depression were calculated for each diagnostic criterion, and existing major depressive criteria were compared to potential alternative criteria currently used for RDC minor depression. Of the subjects in our prevalence sample, 15.4% were found to have major depression; 23.1%, minor depression; and 11.5%, intermittent depression. In our validation sample, two criteria for major depression, self-reproach/guilt and thinking/concentration difficulty, were weakly associated with the final diagnosis of major depression because of poor sensitivity or specificity. In contrast, three possible alternative criteria were significantly associated with the diagnosis of major depression and showed high sensitivity and specificity. These included nonverbal manifestations of depression, irritability/complaining, and demandingness/dependency. We conclude that RDC depressive syndromes are common in probable AD of mild to moderate severity. In the presence of AD, the validity of some existing major depressive criteria may be limited in comparison to several potential alternative criteria because of relatively poor sensitivity and/or specificity.

Entities:  

Mesh:

Year:  1994        PMID: 7826494     DOI: 10.1177/089198879400700409

Source DB:  PubMed          Journal:  J Geriatr Psychiatry Neurol        ISSN: 0891-9887            Impact factor:   2.680


  4 in total

1.  Galantamine in the treatment of minor depression with mild to moderate Alzheimer's dementia in an elderly woman.

Authors:  Kannayiram Alagiakrishnan
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2010

2.  Anti-dementia drugs and co-medication among patients with Alzheimer's disease : investigating real-world drug use in clinical practice using the Swedish Dementia Quality Registry (SveDem).

Authors:  Seyed-Mohammad Fereshtehnejad; Kristina Johnell; Maria Eriksdotter
Journal:  Drugs Aging       Date:  2014-03       Impact factor: 3.923

3.  Development of a new treatment for Alzheimer's disease and Parkinson's disease using anti-aggregatory beta-synuclein-derived peptides.

Authors:  Manfred Windisch; Birgit Hutter-Paier; Edward Rockenstein; Makoto Hashimoto; Margaret Mallory; Eliezer Masliah
Journal:  J Mol Neurosci       Date:  2002 Aug-Oct       Impact factor: 3.444

4.  Antidepressants for treating depression in dementia.

Authors:  Robert Dudas; Reem Malouf; Jenny McCleery; Tom Dening
Journal:  Cochrane Database Syst Rev       Date:  2018-08-31
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.